Chris Schott

Equibles does not estimate personal net worth.

Get an email with a short summary when Merck & Co., Inc. publishes a filing, an earnings call transcript or a press release.

Get MRK alerts

About Chris Schott

Chris Schott has spoken on 1 earnings call across 1 company, most recently for Merck & Co., Inc. on February 3, 2026. Merck & Co., Inc. is classified in the Drug Manufacturers - General industry within the Healthcare sector. Other leadership on record at Merck & Co., Inc. includes Robert M. Davis (CEO, Chairman and Board Member), Jennifer Zachary (General Counsel), Dalton E. Smart III (Chief Accounting Officer) and 7 others.

Chris Schott on recent calls

“Just on MK3000, it's obviously a new mechanism, but also listed as one of your key near-term products for de-risking that $70 billion.”

Other, Merck & Co., Inc. Q4 FY2025 Earnings Call · February 3, 2026

Affiliation history

Merck & Co., Inc. (MRK)
Transcript header (unverified)

Current

Company network

Merck & Co., Inc.

MRK

Current role

Drug Manufacturers - General · Healthcare

1 appearance Latest appearance 2026-02-03

View calls and events

Leadership on record at Merck & Co., Inc.

Robert M. Davis CEO, Chairman, Board Member
Jennifer Zachary General Counsel
Dalton E. Smart III Chief Accounting Officer
Christine E. Seidman Board Member
J.H. Noseworthy Board Member
Kathy J. Warden Board Member
P.B. Rothman Board Member
P.J. Craig Board Member
Paul J. Diaz Board Member
R.B. Lazarus Board Member

Recent activity

Earnings call Merck & Co., Inc. Q4 FY2025 Earnings Call Merck & Co., Inc. (MRK)
2026-02-03